Choice of adjuvant therapy for HER2-positive breast cancer  in real clinical practice: analysis of physician preferences  in the Russian Federation

E. V. Lubennikova; E. V. Artamonova

Medical alphabet
Medicinskij alfavit

ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)

User

eng | рус

Medical alphabet

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Lubennikova E.V., Artamonova E.V. Choice of adjuvant therapy for HER2-positive breast cancer in real clinical practice: analysis of physician preferences in the Russian Federation. Medical alphabet. 2024;(7):7-12. (In Russ.) https://doi.org/10.33667/2078-5631-2024-7-7-12

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)

* not an advertisement

Indexing Databases

* not an advertisement

Popular articles Editors' Choice

Editor-in-Chief

Petrikov Sergey S.

Subscription Login to verify subscription

Article Tools

Finding References

Email this article (Login required)

Email the author (Login required)

About the Authors

E. V. Lubennikova
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation

Lubennikova Elena V. - PhD Med, senior researcher at Dept of Antitumor Drug Therapy No.1 Dept of Drug Treatment

Moscow

E. V. Artamonova
N.N. Blokhin National Medical Research Center of Oncology; Pirogov Russian National Research Medical University; Moscow Regional Research Clinical Institute named after M. F. Vladimirsky
Russian Federation

Artamonova Elena V. - DM Sci (habil.), head of Dept of Antitumor Drug Therapy No.1 Dept of Drug Treatment; professor at Dept of Oncology and Radiation Therapy; head of Dept of Oncology and Thoracic Surgery

Moscow

Notifications

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Medical alphabet

For citations:

Cookies policy